In addition to use of clinical risk scores based on prostate specific antigen (PSA), tumor grade and stage,3, 4 baseline molecular characterization of diagnostic biopsies offers the potential to identify patients at high risk of post‐RT relapse. Here, KLK3 is linked to neoplasm.